Tecan Group AG (SWX:TECN) is seeking M&A. Achim von Leoprechting Chief Executive Officer said during the 41st Annual JPMorgan Healthcare Conference, "I think one of our core capabilities to bridge innovation from research all the way into the clinical side is something that we see as a very, very strong competitive asset. And we continue to focus on applications that we identify having the highest growth potential and impact potential for the journey from research into the clinic. And lastly, with our strong financials, we are in a very good position also to continue the reinvestment into company both from an organic R&D and sales and marketing and service perspective, but also from an inorganic M&A perspective".
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
319.6 CHF | +1.14% | -3.27% | -6.93% |
18/04 | Tecan Group Approves Dividend, Payable on April 24, 2024 | CI |
18/04 | Tecan Group Elects Monica Manotas as Additional Independent Member of the Board of Directors | CI |
EPS Revisions
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-6.93% | 4.43B | |
+2.92% | 7.71B | |
-4.25% | 2.99B | |
+4.17% | 2.12B | |
-32.55% | 1.03B | |
+9.01% | 994M | |
-1.44% | 866M | |
-47.44% | 831M | |
-31.67% | 670M | |
-26.49% | 654M |
- Stock Market
- Equities
- TECN Stock
- News Tecan Group AG
- Tecan Group Seeks M&A